Cargando…
Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy
Despite the significant progress of modern anticancer therapies, multiple myeloma (MM) is still incurable for the majority of patients. Following almost three decades of development, chimeric antigen receptor (CAR) T-cell therapy now has the opportunity to revolutionize the treatment landscape and m...
Autores principales: | Grywalska, Ewelina, Sosnowska-Pasiarska, Barbara, Smok-Kalwat, Jolanta, Pasiarski, Marcin, Niedźwiedzka-Rystwej, Paulina, Roliński, Jacek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226998/ https://www.ncbi.nlm.nih.gov/pubmed/32316105 http://dx.doi.org/10.3390/cells9040983 |
Ejemplares similares
-
CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer
por: Bębnowska, Dominika, et al.
Publicado: (2020) -
Chronic Lymphocytic Leukemia-Induced Humoral Immunosuppression: A Systematic Review
por: Grywalska, Ewelina, et al.
Publicado: (2020) -
Immunological Prognostic Factors in Multiple Myeloma
por: Bębnowska, Dominika, et al.
Publicado: (2021) -
Toll-like Receptor 2 as a Marker Molecule of Advanced Ovarian Cancer
por: Sobstyl, Małgorzata, et al.
Publicado: (2021) -
Expression of CTLA-4 and CD86 Antigens and Epstein-Barr Virus Reactivation in Chronic Lymphocytic Leukemia—Any Link with Known Prognostic Factors?
por: Grywalska, Ewelina, et al.
Publicado: (2022)